Kalmeda Tinnitus Study

Not Applicable

• Conditions: H93.1; Tinnitus

• Registration Number: DRKS00022973
• Lead Sponsor: mynoise GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-09
• Study Completion: 2022-03-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 187

Inclusion Criteria

Chronic tinnitus longer than 3 months

Exclusion Criteria

psychological diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome variable of the study is the total score of the tinnitus questionnaire by Göbel and Hiller. It is primarily used to assess the effectiveness of Kalmeda. The primary endpoint is defined as the tinnitus burden after three months.

Secondary Outcome Measures

Name	Time	Method
As secondary endpoints, the respective changes in tinnitus burden, depression tendency, stress experience and self-efficacy after 12 months (control group) or 9 months (intervention group) are selected.